Italia markets open in 4 hours 33 minutes

CRSP Jan 2025 95.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,8000-0,3500 (-16,28%)
In data: 03:41PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente2,1500
Aperto1,9000
Denaro1,5500
Domanda2,0500
Prezzo d'esercizio95,00
Scadenza2025-01-17
Min-Max giorno1,8000 - 1,9000
Contratto - Min-MaxN/D
Volume6
Open Interest410
  • GlobeNewswire

    CRISPR Therapeutics Proposes New Appointment to the Board of Directors

    ZUG, Switzerland and BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Sandy Mahatme, LL.M. to its Board of Directors at the Company’s next annual general meeting to be held in 2024. “I am honored to welcome Sandy to our Board during an important time in CRISPR Therapeutics’ continued evolution,” said Samarth Kulkarni, Ph.D., C

  • GlobeNewswire

    CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

    ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023. Title: Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CAR T cell

  • GlobeNewswire

    CRISPR Therapeutics Announces Leadership Transition

    -CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023--Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue serving as CEO of the Company- ZUG, Switzerland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Rodger Novak, M.D., President and Chairman